A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease

Differentiating between pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) is crucial for the appropriate course of treatment, especially with advancements in the role of neoadjuvant chemotherapies for PDAC, compared to CCA. Furthermore, benign pancreaticobiliary diseases can mimic...

Descripción completa

Detalles Bibliográficos
Autores principales: Mato Prado, Mireia, Puik, Jisce R., Castellano, Leandro, López-Jiménez, Elena, Liu, Daniel S. K., Meijer, Laura L., Le Large, Tessa Y. S., Rees, Eleanor, Funel, Niccola, Sivakumar, Shivan, Pereira, Stephen P., Kazemier, Geert, Zonderhuis, Babs M., Erdmann, Joris I., Swijnenburg, Rutger-Jan, Frilling, Andrea, Jiao, Long R., Stebbing, Justin, Giovannetti, Elisa, Krell, Jonathan, Frampton, Adam E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693033/
https://www.ncbi.nlm.nih.gov/pubmed/38041102
http://dx.doi.org/10.1186/s40164-023-00458-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693033/
https://www.ncbi.nlm.nih.gov/pubmed/38041102
http://dx.doi.org/10.1186/s40164-023-00458-3

Ejemplares similares